1. Home
  2. PRCH vs ABCL Comparison

PRCH vs ABCL Comparison

Compare PRCH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRCH

Porch Group Inc.

HOLD

Current Price

$10.16

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCH
ABCL
Founded
2012
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PRCH
ABCL
Price
$10.16
$5.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$18.63
$8.40
AVG Volume (30 Days)
2.3M
8.5M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
10.91
EPS
N/A
N/A
Revenue
$482,414,000.00
$75,128,000.00
Revenue This Year
$4.15
N/A
Revenue Next Year
$17.05
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
10.18
160.56
52 Week Low
$6.36
$1.98
52 Week High
$19.44
$6.52

Technical Indicators

Market Signals
Indicator
PRCH
ABCL
Relative Strength Index (RSI) 56.91 66.96
Support Level $8.93 $5.34
Resistance Level $10.85 $5.63
Average True Range (ATR) 0.57 0.43
MACD -0.14 0.05
Stochastic Oscillator 34.46 87.28

Price Performance

Historical Comparison
PRCH
ABCL

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: